Skip to main content
. 2021 Mar 12;2021(3):CD013316. doi: 10.1002/14651858.CD013316.pub2

Rapp 2018.

Study name GlioVax
Starting date March 2018
Contact information Michael Sabel (Michael.Sabel@med.uni‐duesseldorf.de)
Notes Trial identifier: EudraCT‐Number 2017–000304‐14
Country: Germany
Inclusion criteria: monofocal GBM, IDH wild‐type; near‐complete resection (≤ 5 mL residual tumour volume); Karnofsky performance status ≥ 70%

GBM: glioblastoma; IDH: isocitrate dehydrogenase.